Addiction

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast...

UNIVERSITY OF MARYLAND, BALTIMORE AND AXIS RESEARCH & TECHNOLOGIES ANNOUNCE JOINT VENTURE TO BUILD NATION’S FIRST AI-POWERED SMART SURGICAL PERFORMANCE CENTER

New 36,000 sq. ft. facility will leverage OMNIMED SmartOR™ technology to integrate AI-driven data and performance analytics into surgical training, research,...

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI,...

Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market

Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwideVANCOUVER, British Columbia, Sept. 30, 2025...

Shoreline Recovery Center Marks International Overdose Awareness Day, Honoring Families, First Responders, and Recovery Advocates

The Encinitas facility shines a light on families, first responders, and individuals in recovery while calling for education, compassion, and...

error: Content is protected !!